MAP2K1 mutation
|
NSCLC
|
MAP2K1 mutation
|
NSCLC
|
lorlatinib Resistant: C3 – Early Trials
|
lorlatinib Resistant: C3 – Early Trials
|
MAP2K1 mutation
|
Melanoma
|
MAP2K1 mutation
|
Melanoma
|
CTLA4 inhibitor Sensitive: C3 – Early Trials
|
CTLA4 inhibitor Sensitive: C3 – Early Trials
|
MAP2K1 mutation
|
Biliary Tract Cancer
|
MAP2K1 mutation
|
Biliary Tract Cancer
|
trametinib Sensitive: C3 – Early Trials
|
trametinib Sensitive: C3 – Early Trials
|
MAP2K1 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
MAP2K1 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
binimetinib Sensitive: C3 – Early Trials
|
binimetinib Sensitive: C3 – Early Trials
|
MAP2K1 mutation
|
Pancreatic Ductal Adenocarcinoma
|
MAP2K1 mutation
|
Pancreatic Ductal Adenocarcinoma
|
avelumab + binimetinib Sensitive: C3 – Early Trials
|
avelumab + binimetinib Sensitive: C3 – Early Trials
|
MAP2K1 mutation
|
Ovarian Cancer
|
MAP2K1 mutation
|
Ovarian Cancer
|
selumetinib Sensitive: C4 – Case Studies
|
selumetinib Sensitive: C4 – Case Studies
|
MAP2K1 mutation
|
Melanoma
|
MAP2K1 mutation
|
Melanoma
|
dabrafenib Resistant: D – Preclinical
|
dabrafenib Resistant: D – Preclinical
|
MAP2K1 mutation
|
Melanoma
|
MAP2K1 mutation
|
Melanoma
|
trametinib Resistant: D – Preclinical
|
trametinib Resistant: D – Preclinical
|